Every 8-K that Cvrx, Inc. (CVRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CVRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVRX filings page.
CVRx, Inc. reported that the employment of Chief Revenue Officer Robert John terminated effective immediately on August 10, 2026, under circumstances that entitle him to severance pay and benefits in line with his employment agreement. The company also announced a sales leadership transition in which Paul Verrastro, a long-time CVRx executive with more than 30 years of medical device sales and marketing experience, has been appointed Interim Head of Sales effective immediately while a search for a permanent successor is conducted. Management stated that a revised commercial outlook and the need to improve commercial execution led to the change in sales leadership.
CVRx, Inc. reported second quarter 2026 revenue of $15.7 million, up 16% from the prior-year quarter, driven mainly by U.S. heart failure sales. U.S. revenue was $14.8 million with 466 revenue units and 258 active implanting centers, while Europe revenue declined to $0.9 million on 40 units.
Gross profit rose to $13.7 million and gross margin improved to 87% from 84% a year earlier. Operating expenses were $26.7 million, resulting in a net loss of $14.0 million, or $0.53 per share, slightly better than the $14.7 million loss, or $0.57 per share, in 2025. Cash and cash equivalents totaled $64.6 million, and long-term debt was $58.6 million as of June 30, 2026.
Humana adopted a Medicare Advantage coverage policy for Barostim effective May 1, 2026, covering FDA-approved and BENEFIT-HF trial patients; management describes this as the third significant reimbursement development this year. For the third quarter of 2026, the company expects total revenue between $13.5 million and $14.5 million and notes headwinds from fewer sales territories, lower sales force productivity, and challenges with a large payer.
CVRx, Inc. announced that Chief Financial Officer Jared Oasheim has notified the company of his intention to resign to pursue other professional opportunities. He will remain CFO and principal accounting officer until a successor starts, then stay employed full-time at his current base salary until at least August 31, 2026 or 30 days after the transition.
Under an Employment Transition Agreement dated June 8, 2026, he will be available as a consultant through February 2027 at $245 per hour. He remains eligible for his full 2026 cash incentive payout based on the company’s actual results, will receive $262,000 in transition-related cash payments in two installments, and has the post-termination exercise period for certain pre-July 2021 stock options extended to three months after the consulting period. CVRx will also reimburse up to $10,000 of his legal fees for reviewing the agreement and has begun a search for the next CFO.
CVRx, Inc. reported the results of its 2026 annual meeting of stockholders held on June 1, 2026. Stockholders elected three Class II directors — Michael Dale, Kevin Hykes, and Joseph Slattery — to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Dale received 13,261,467 votes for and 24,036 withheld, Hykes received 12,040,949 for and 1,244,554 withheld, and Slattery received 11,938,599 for and 1,346,904 withheld, with 10,153,679 broker non-votes on each nominee.
Stockholders also ratified the appointment of Grant Thornton LLP as CVRx’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The auditor ratification received 21,150,201 votes for, 2,275,126 against, and 13,855 abstentions, indicating strong support for continuing with Grant Thornton LLP.
CVRx, Inc. reported first quarter 2026 revenue of $14.8 million, up 20% from $12.3 million a year earlier, driven mainly by U.S. sales growth. U.S. revenue reached $13.7 million, while Europe contributed $1.1 million.
Gross profit was $12.9 million with gross margin improving to 87% from 84%. Operating expenses rose to $25.0 million, and net loss was $13.1 million, or $0.50 per share, slightly better than the $13.8 million, or $0.53 per share, loss in 2025. Cash and cash equivalents totaled $72.3 million at March 31, 2026.
The company activated the first site and enrolled the first patient in its BENEFIT-HF trial, which is designed to assess whether Barostim can help a broader group of heart failure patients. For the second quarter of 2026, CVRx expects revenue between $15.1 million and $16.1 million and maintained its full-year 2026 revenue and expense guidance while updating its gross margin outlook.
CVRx, Inc. reported preliminary first quarter 2026 results showing total revenue of $14.7–$14.8 million, up from $12.3 million a year earlier, which is about 20% growth. Gross margin is expected to improve to roughly 87% from 84%, while total operating expenses are projected at about $25 million versus $23.7 million.
As of March 31, 2026, CVRx had 257 U.S. active implanting centers and 56 U.S. sales territories, and held approximately $72.3 million in cash and cash equivalents. The company highlights improved reimbursement after Category I CPT codes took effect, with 30‑day Medicare Advantage prior authorization approval rates rising from 31% in 2024 to 44% in 2025 and 50% for the first two months of 2026.
CVRx also activated the first site in its BENEFIT‑HF randomized trial on March 31, 2026, with enrollment expected to begin in the second quarter. If successful, this study could expand the indicated patient population for Barostim by about three times.
CVRx, Inc. approved a new performance stock unit (PSU) program for its executive officers tied to a cumulative revenue goal over the fiscal 2026–2027 period. This incremental award is in addition to their regular annual equity grants.
For named executive officers, the grant date value of these PSUs equals three-fourths of their 2026 annual long-term incentive value. Payouts range from 50% of target at threshold performance to 200% at maximum. Any earned PSUs vest 50% after the revenue goal is certified and 50% on December 31, 2028, generally requiring continued employment and including provisions for accelerated or continued vesting upon death, disability, certain terminations, or qualifying change in control events.
CVRx, Inc. reported fourth quarter 2025 revenue of $16.0 million, up 4% year over year, with U.S. revenue of $14.9 million and gross margin improving to 86%. The company remained unprofitable, posting a quarterly net loss of $11.9 million, or $0.46 per share.
For full year 2025, revenue reached $56.7 million, a 10% increase, while net loss narrowed to $53.3 million from $60.0 million. CVRx expanded to 252 active implanting centers and 53 U.S. sales territories, and maintained a high 85% gross margin.
The company initiated the large BENEFIT-HF trial, targeting up to 2,500 patients and potential threefold expansion of the Barostim addressable market, with expected net costs of $20–$30 million over five to seven years. CVRx also upsized its Innovatus debt facility to up to $100 million and borrowed an additional $10 million, ending 2025 with $75.7 million in cash and cash equivalents and guiding 2026 revenue to $63.0–$67.0 million.
CVRx, Inc. entered into an Open Market Sale Agreement with Jefferies LLC that allows the company to offer and sell shares of its common stock in an at-the-market program. Under this arrangement, CVRx may issue shares with an aggregate offering amount of up to $50.0 million, from time to time, through Jefferies acting as sales agent.
Any sales will be made as at-the-market offerings under an effective Form S-3 shelf registration and related prospectus supplement. Jefferies will receive a commission of up to 3.0% of the gross proceeds from any shares sold, and CVRx will also cover certain related expenses. The company states that it intends to use any net proceeds primarily for working capital and general corporate purposes, and is not obligated to sell any specific amount under the agreement.
CVRx, Inc. amended its term loan agreement on January 9, 2026, increasing total term loan availability by $50 million to up to $100 million, extending interest-only payments to four years from the closing date and pushing final maturity to May 9, 2031. The interest rate is now a floating rate equal to the greater of the prime rate or 6.75%, plus a margin of 2.65%, which falls to 2.00% after two consecutive quarters of positive adjusted EBITDA. The company immediately borrowed an additional $10 million, bringing total term loans outstanding to $60 million, and may draw a further $40 million if future revenue and market capitalization milestones are met.
CVRx expects fourth-quarter 2025 revenue of about $15.9–$16.1 million, up roughly 4–5% from $15.3 million a year earlier, and full-year 2025 revenue of about $56.5–$56.7 million, up 10–11% from $51.3 million in 2024. As of December 31, 2025, it had $75.7 million in cash and cash equivalents, 252 active implanting centers, and 53 U.S. sales territories.
The FDA granted an investigational device exemption for the BENEFIT-HF trial of the Barostim device in an expanded heart failure population. CVRx has applied to CMS for IDE Category B coverage; if approved, it plans to enroll across about 150 centers in the first half of 2026, with enrollment expected to complete within five years and a two-year follow-up. Net trial costs are expected at $20–$30 million, and a successful outcome could expand Barostim’s U.S. addressable market from roughly 339,000 to 983,000 patients, increasing the estimated sales opportunity from $10.5 billion to $30.5 billion.
CVRx, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The disclosure was made under Item 2.02, and the press release is included as Exhibit 99.1 and incorporated by reference.
The company states this information is being furnished, not filed, under the Exchange Act. CVRx’s common stock trades on the Nasdaq Global Select Market under the symbol CVRX.